Penumbra, Inc. (PEN)
NEUTRALFondamental
67
Prix
$324.74
Capitalisation boursière
$12.79B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Penumbra designs and manufactures devices that remove blood clots from inside the body without open surgery, threading a catheter through a blood vessel to pull the clot out or suck it away. Its products treat conditions such as ischemic stroke, pulmonary embolism and acute limb ischemia. A second, related line of products helps physicians access blood vessels and block off unwanted ones, such as before a tumor is removed. It sells to hospitals and clinics in over 100 countries.
Comment l'entreprise gagne de l'argent
Penumbra sells physical devices — catheters, aspiration systems and related disposables — to hospitals, which use them one procedure at a time. Because each stroke, clot or vascular case consumes a new device, revenue grows with the number of procedures performed rather than through subscriptions, and it depends on hospitals adopting Penumbra's technology over rival devices, on regulatory clearance for new products, and on reimbursement from insurers and public health systems that pay for the procedure.
Chiffre d'affaires par segment
Devices that remove blood clots to treat pulmonary embolism, deep vein thrombosis, acute limb ischemia, ischemic stroke and coronary disease.
Devices that help physicians access blood vessels and selectively block off unwanted ones, used in a range of vascular procedures.
Avantage concurrentiel
Brevets et licences · ÉtroitPenumbra's devices are protected by patents on their specific mechanical and aspiration designs, and any new device must clear a lengthy regulatory approval process before it can be sold, which slows down copycats. That said, the field has several capable competitors building similar clot-removal technology, so the protection is real but not close to exclusive.
Ce qui stimule la demande
DéfensifPenumbra's core products treat medical emergencies such as stroke, pulmonary embolism and limb-threatening blood clots, procedures that hospitals perform regardless of the economic climate because delaying them risks death or permanent disability. Demand is therefore driven mainly by disease incidence, physician adoption of minimally invasive techniques, and hospital budgets for equipment, not by discretionary consumer spending.
Principaux risques
- Lengthy and uncertain regulatory approval — The company operates under stringent domestic and foreign medical device regulations, and delays or failures in obtaining approval for new or modified products can push back launches and revenue.
- Product liability litigation — As a maker of devices used in life-critical procedures, the company faces product liability claims and lawsuits seeking compensatory and punitive damages over alleged device failures or injuries.
- Restrictions on off-label promotion — Regulators actively enforce rules against promoting a device for uses it was not approved for, and a violation can bring substantial monetary penalties or criminal prosecution.
- Mandatory adverse event reporting — Medical device reporting rules require the company to notify regulators whenever it learns a device may have caused or contributed to a death or serious injury, which can trigger investigations or recalls.
Les arguments en faveur
Buyers argue that thrombectomy is still replacing older, less effective treatments for stroke and clot-related emergencies, that Penumbra's revenue keeps growing faster than the market, and that its second embolization and access line adds a further avenue for growth beyond its original thrombectomy business.
Les arguments contre
Sellers fear that well-funded competitors are developing similar clot-removal technology, that a single unfavorable regulatory finding or product-liability case could damage both revenue and reputation quickly, and that a business built on emergency procedures leaves little room to grow through pricing.
Written by the editors, published on 18 août 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$1.50B
12 derniers mois (au 30/06/2026)
Résultat net
$161M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$175M
Capitaux propres totaux
$1.43B
Passif total
$399M
Ratio de liquidité général
5.75
Couverture des intérêts
144.33
Dette/EBITDA
1.03
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$238.51
Prix actuel
$324.74
Marge de sécurité
-36.2%
Fourchette de juste valeur
$155.03 - $321.99
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
79.55
ROE
12.4%
Ratio P/B
8.33
P/FCF
59.06
Marge brute
67.8%
ROIC
8.5%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
8.5%
WACC
8.2%
ROIC − WACC
+0.3 pp
ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.
Critères d'analyse fondamentale
Réussi (18)
- EPS shows upward trend
- EPS CAGR 33.58%
- Price CAGR 17.69%
- ROIC 8.5%
- Gross Margin 67.8%
- Debt/Equity ratio
- Operating Margin 12.4%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 11.1%
- Revenue Growth 5Y 20.2%
- Earnings Quality (OCF/NI) 1.73
- Share Dilution 1.0%
- Piotroski F-Score 8/9
Échoué (8)
- P/FCF 59.06
- P/B Ratio 8.33
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 30% Buy
- Earnings Surprise avg -10.5%
- Net Margin Trend 10.7% vs 11.5%
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Le nombre d'actions est stable
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Adam Elsesser J.D. | Co-Founder, Chairman & CEO | 63 |
| Ms. Shruthi Narayan | President | 40 |
| Dr. Arani Bose M.D. | Co-Founder & Director | 63 |
| Ms. Maggie S. Yuen | Chief Financial Officer | 53 |
| Mr. Lambert Shiu | Chief Accounting Officer | 45 |
| Ms. Johanna Roberts J.D. | Executive VP, General Counsel & Secretary | 53 |
| Mr. Ben Sorci | Executive Vice President of Operations | - |
| Mr. Pankaj Tiwari | Executive VP & Chief Information Officer | - |
Risque d'audit
7
Risque du conseil
5
Risque de rémunération
7
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for PEN, sourced from Markets Gazette.
- 2/25/2026NEUTRALPenumbra Q4 Earnings Assessment
The financial community is keenly awaiting the assessment of Penumbra Inc.'s fourth-quarter earnings. While specific details from this analysis have not yet been released, investor attention remains high, given the critical importance of such reports in gauging the medical device company's financial health and future prospects. Q4 performance is particularly crucial for Penumbra, operating in a competitive medical technology market where innovation and clinical outcomes drive growth. Analysts will be closely scrutinizing key metrics such as revenue figures, profit margins, and forward-looking guidance for the upcoming year, seeking indications of the company's ability to sustain its growth trajectory and navigate industry challenges. The full disclosure of these results will provide clear direction for the stock.
via Markets Gazette